Xiamen Amoytop Biotech Co Ltd (688278) - Total Assets
Based on the latest financial reports, Xiamen Amoytop Biotech Co Ltd (688278) holds total assets worth CN¥3.21 Billion CNY (≈ $469.63 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 688278 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Xiamen Amoytop Biotech Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Xiamen Amoytop Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Xiamen Amoytop Biotech Co Ltd for net asset value and shareholders' equity analysis.
Xiamen Amoytop Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Xiamen Amoytop Biotech Co Ltd's total assets of CN¥3.21 Billion consist of 59.9% current assets and 40.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.2% |
| Accounts Receivable | CN¥771.50 Million | 25.3% |
| Inventory | CN¥263.55 Million | 8.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥379.74 Million | 12.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Xiamen Amoytop Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Xiamen Amoytop Biotech Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xiamen Amoytop Biotech Co Ltd's current assets represent 59.9% of total assets in 2024, an increase from 47.0% in 2016.
- Cash Position: Cash and equivalents constituted 12.2% of total assets in 2024, down from 21.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 37.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 25.3% of total assets.
Xiamen Amoytop Biotech Co Ltd Competitors by Total Assets
Key competitors of Xiamen Amoytop Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Xiamen Amoytop Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.20 | 4.07 | 7.92 |
| Quick Ratio | 4.30 | 3.34 | 6.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.51 Billion | CN¥968.64 Million | CN¥644.33 Million |
Xiamen Amoytop Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Xiamen Amoytop Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.41 |
| Latest Market Cap to Assets Ratio | 1.07 |
| Asset Growth Rate (YoY) | 29.5% |
| Total Assets | CN¥3.05 Billion |
| Market Capitalization | $3.26 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Xiamen Amoytop Biotech Co Ltd's assets above their book value (1.07x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Xiamen Amoytop Biotech Co Ltd's assets grew by 29.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below shows the annual total assets of Xiamen Amoytop Biotech Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.05 Billion ≈ $446.37 Million |
+29.47% |
| 2023-12-31 | CN¥2.36 Billion ≈ $344.77 Million |
+33.22% |
| 2022-12-31 | CN¥1.77 Billion ≈ $258.80 Million |
+24.18% |
| 2021-12-31 | CN¥1.42 Billion ≈ $208.40 Million |
+19.40% |
| 2020-12-31 | CN¥1.19 Billion ≈ $174.53 Million |
+51.01% |
| 2019-12-31 | CN¥789.83 Million ≈ $115.58 Million |
+11.59% |
| 2018-12-31 | CN¥707.77 Million ≈ $103.57 Million |
+11.09% |
| 2017-12-31 | CN¥637.12 Million ≈ $93.23 Million |
-0.85% |
| 2016-12-31 | CN¥642.58 Million ≈ $94.03 Million |
-- |
About Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.